太阳集团5493||欢迎登录

Be the most trusted biotech company

2024-11-19

Henlius to Showcase Latest Results of 5 Clinical Trails at ESMO Asia 2024
2024-11-07

Henlius and SVAX Forge Strategic Partnership in the MENAT Market
2024-11-05

Latest Research into the Differentiated Mechanisms of Action of Serplulimab Published in mAbs Journal
2024-10-30

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
2024-10-24

First Patient in Japan Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab
2024-10-23

HLX22 Dual HER2 Blockade Therapy Featured on the Cover of Med
2024-10-21

Henlius Receives Approval in Japan for Phase 3 MRCT of Dual HER2 Blockade Therapy on First-Line HER2+ GC
2024-10-14

Henlius Shines at CPHI Worldwide 2024, Expanding New Opportunities for International Collaboration
2024-09-30

Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11